Skip to content
Screener

Illumina ILMN Contract Liabilities

Contract Liabilities at other companies

Azenta logo
AzentaAZTA
$39.5M
Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
$3.34M-41.5%
Guardant Health logo
Guardant HealthGH
$8.9M+15.6%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$7.1M+257%
Natera, Inc. logo
Natera, Inc.NTRA
$17M
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$10.14M-19.3%

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Gross profit$770.0M+10.8%
Operating income$245.0M+14.5%
Net income$207.0M-11.9%
EPS (diluted)$1.35-9.4%

Balance sheet

See full
Cash & equivalents$1.0B+11.3%
Total debt$1.9B-7.3%
Total equity$2.8B+25.7%
Total assets$6.7B+9.2%

Cash flow

See full
Operating cash flow$201.0M-14.1%
CapEx$39.0M+30.0%
Free cash flow$162.0M-20.6%

Valuation

See full
Market cap$30.18B+102%
Enterprise value$31.09B+92.9%
P/E36.6×+24.7×
P/S6.7×+3.2×

Profitability

See full
Gross margin66.4%-0.2pp
Operating margin19.6%
Net margin18.4%-11.0pp
FCF margin20.7%-3.3pp

Returns & leverage

See full
Return on equity32.4%-35.7pp
Debt / equity0.7×-0.2×
Current ratio1.8×0.0×

Where this comes from

Reported directly by Illumina in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The source filing: Illumina’s 10-Q, filed May 4, 2026.

Filed
May 3, 2026, 8:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001110803-26-000092

Contract liabilities, which consist of deferred revenue and customer deposits, as of March 29, 2026 and December 28, 2025, were $344 million and $346 million, respectively, of which the short-term portions of $269 million and $270 million, respectively, were recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded in Q1 2026 included $98 million of previously deferred revenue that was included in contract liabilities as of December 28, 2025.

Cover / Front Matter

FAQ

What is Illumina's contract liabilities?
Illumina (ILMN) reported contract liabilities of $344M in Q1 2026.
How has Illumina's contract liabilities changed year-over-year?
Illumina's contract liabilities increased by 4.6% year-over-year, from $329M to $344M.
What is the long-term trend for Illumina's contract liabilities?
Over 5 years (2020 to 2025), Illumina's contract liabilities has grown at a 8.5% compound annual growth rate (CAGR), from $230M to $346M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.

Ask your AI about Illumina's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude